Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Melissa Galloway

Nurse Practitioner Georgetown, DE Nurse Practitioner

NPI 1245018878 CMS profile 11489193

20930 Dupont Blvd, Georgetown, DE 19947

Open in the dashboard

General payments

$2,718

125 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Galloway of Georgetown, DE is reported in the CMS Open Payments database as having received $2,718 across 125 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $489 17
2024 General $1,967 96
2023 General $262 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Galloway
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Melissa Galloway were reported at $489. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Melissa Galloway Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $262 $166 $54–$529 $160
2024 $1,967 $173 $55–$556 $164
2025 $489 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $316 15 payments
  2. AbbVie, Inc. $296 16 payments
  3. Exact Sciences Corporation $206 8 payments
  4. Lilly USA, LLC $179 8 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $173 10 payments
  6. Ardelyx, Inc. $162 2 payments
  7. GlaxoSmithKline, LLC. $151 8 payments
  8. Corcept Therapeutics $119 4 payments
  9. Novo Nordisk Inc $113 6 payments
  10. Pfizer Inc. $112 6 payments
  11. Other $891 42 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,718 125 payments
Products named General payments · program years 2023–2025
  1. AIRSUPRA $173 8 payments
  2. Kerendia $173 10 payments
  3. Cologuard Collection Kit $172 7 payments
  4. IBSRELA $162 2 payments
  5. TRELEGY ELLIPTA $133 7 payments
  6. JARDIANCE $132 6 payments
  7. BREZTRI $130 6 payments
  8. UBRELVY $121 6 payments
  9. Korlym $119 4 payments
  10. Ozempic $113 6 payments
  11. Other $1,853 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

873

Median for Nurse Practitioner: 389

Drug cost

$90,759

Median for Nurse Practitioner: $21,885

Branded share of claims

11.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 20 $26,103
Jardiance Empagliflozin Brand 19 $18,691
Rybelsus Semaglutide Brand 17 $18,415
Eliquis Apixaban Brand 11 $12,012
Myrbetriq Mirabegron Brand 14 $6,608
Tramadol Hcl Generic 109 $1,286
Atorvastatin Calcium Generic 49 $940
Zolpidem Tartrate Generic 89 $877
Glycopyrrolate Generic 14 $638
Omeprazole Generic 40 $528

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $155
$155 — —
JARDIANCE
  • Lilly USA, LLC $81
  • Boehringer Ingelheim Pharmaceuticals, Inc. $62
$142 19 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $131
$131 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $130
$130 — —
VRAYLAR
  • AbbVie, Inc. $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

125 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record